Antibiotics for irritable bowel syndrome: rationale and current evidence (Q34642080)

3 August 2017

Antibiotics for irritable bowel syndrome: rationale and current evidence (English)

1 reference

3 August 2017

0 references

irritable bowel syndrome

1 reference

2

Mark Pimentel

1 reference

3 August 2017

Amit H Sachdev

1

1 reference

3 August 2017

1 October 2012

1 reference

Current gastroenterology reports

3 August 2017

1 reference

3 August 2017

14

1 reference

3 August 2017

5

1 reference

3 August 2017

439-445

1 reference

https://scigraph.springernature.com/pub.10.1007/s11894-012-0284-2

3 August 2017

0 references

cites work

Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Functional bowel disorders and functional abdominal pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Pathophysiology underlying irritable bowel syndrome--from the viewpoint of dysfunction of autonomic nervous system activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The role of stress in symptom exacerbation among IBS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Irritable bowel syndrome and small intestinal bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Metagenomic analysis of the human distal gut microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The human microbiome project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The indigenous gastrointestinal microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Bacterial diversity in the human gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Host-bacterial mutualism in the human intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The gut flora as a forgotten organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Microbial ecology of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Development of the human infant intestinal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Inflammation and microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Gut microbiota in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The gut microbiome as therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The role of the gut microbiota in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

New pathophysiological mechanisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Evaluating a bacterial hypothesis in IBS using a modification of Koch's postulates: part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Alterations in the intestinal microbiota and functional bowel symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Microbial ecology: human gut microbes associated with obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Irritable Bowel Syndrome: Bacterial Overgrowth--What's Known and What to Do.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

A systematic review of diagnostic tests for small intestinal bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Methane and the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Use and abuse of hydrogen breath tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Relationships among the lactulose breath test, intestinal gas volume, and gastrointestinal symptoms in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

A new rat model links two contemporary theories in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Advances in the management of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Management of small intestinal bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Rifaximin: in vitro and in vivo antibacterial activity--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0284-2

Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.

21 January 2018

1 reference

12 December 2020

Bacterial overgrowth of the gastrointestinal tract.

1 reference

12 December 2020

Small intestine bacterial overgrowth

1 reference

12 December 2020

Guidelines--Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders

1 reference

12 December 2020

Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome

1 reference

12 December 2020

A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease

1 reference

12 December 2020

Functional bowel disorders in apparently healthy people

1 reference

12 December 2020

Antibiotics for the treatment of irritable bowel syndrome

1 reference

12 December 2020

Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora.

1 reference

12 December 2020

Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis

1 reference

12 December 2020

The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: IBS vs healthy controls (not historical definitions).

1 reference

12 December 2020

Rome III: New standard for functional gastrointestinal disorders

1 reference

12 December 2020

New perspectives on the role of the intestinal flora in health and disease

1 reference

12 December 2020

In vitro activity of rifaximin and rifampicin against some anaerobic bacteria

1 reference

12 December 2020

Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin

1 reference

12 December 2020

Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction

1 reference

12 December 2020

TLR4 and Insulin Resistance

1 reference

12 December 2020

In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.

1 reference

12 December 2020

Irritable bowel syndrome

1 reference

12 December 2020

The contribution of the large intestine to energy supplies in man

1 reference

12 December 2020

The relationship between daily life stress and gastrointestinal symptoms in women with irritable bowel syndrome

1 reference

12 December 2020

Bacterial concepts in irritable bowel syndrome

1 reference

12 December 2020

Developmental microbial ecology of the neonatal gastrointestinal tract

1 reference

12 December 2020

Intestinal flora in health and disease

1 reference

12 December 2020

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

1 reference

12 December 2020

The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing

1 reference

12 December 2020

Methane on breath testing is associated with constipation: a systematic review and meta-analysis

1 reference

12 December 2020

10.1007/S11894-012-0284-2

Identifiers

DOI

1 reference

PubMed ID

22945316

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

22945316